Aralez Pharmaceuticals Inc (NASDAQ:ARLZ)’s share price rose 16.7% during mid-day trading on Friday . The company traded as high as $2.00 and last traded at $1.96. Approximately 2,280,900 shares were traded during mid-day trading, an increase of 200% from the average daily volume of 759,400 shares. The stock had previously closed at $1.68.

The company has a quick ratio of 0.92, a current ratio of 1.00 and a debt-to-equity ratio of 4.64. The company has a market capitalization of $131.10, a price-to-earnings ratio of -1.17 and a beta of 1.30.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Thursday, November 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. Aralez Pharmaceuticals had a negative return on equity of 118.13% and a negative net margin of 112.89%. The business had revenue of $24.30 million during the quarter, compared to analysts’ expectations of $22.87 million. During the same quarter in the prior year, the firm earned ($0.32) EPS. The business’s revenue for the quarter was up 78.7% compared to the same quarter last year. equities analysts predict that Aralez Pharmaceuticals Inc will post -1.54 EPS for the current year.

In other news, Director Arthur S. Kirsch bought 50,000 shares of the stock in a transaction on Friday, December 8th. The stock was acquired at an average price of $1.47 per share, with a total value of $73,500.00. Following the acquisition, the director now directly owns 271,609 shares in the company, valued at $399,265.23. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.70% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN increased its stake in shares of Aralez Pharmaceuticals by 71.3% in the third quarter. Wells Fargo & Company MN now owns 273,130 shares of the company’s stock valued at $625,000 after buying an additional 113,720 shares during the period. Ballentine Partners LLC increased its stake in shares of Aralez Pharmaceuticals by 166.7% in the third quarter. Ballentine Partners LLC now owns 80,000 shares of the company’s stock valued at $183,000 after buying an additional 50,000 shares during the period. Brown Advisory Securities LLC acquired a new stake in shares of Aralez Pharmaceuticals in the third quarter valued at about $394,000. Intrinsic Edge Capital Management LLC acquired a new stake in shares of Aralez Pharmaceuticals in the second quarter valued at about $270,000. Finally, GSA Capital Partners LLP increased its stake in shares of Aralez Pharmaceuticals by 88.5% in the second quarter. GSA Capital Partners LLP now owns 541,795 shares of the company’s stock valued at $731,000 after buying an additional 254,400 shares during the period. 19.41% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/aralez-pharmaceuticals-arlz-stock-price-up-16-7/1814210.html.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.